Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies
- PMID: 35879846
- DOI: 10.4140/TCP.n.2022.329
Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies
Abstract
Objective To review the data informing the US Food and Drug Administration (FDA) approval for aducanumab for mild cognitive impairment (MCI) and mild Alzheimer's disease (AD). Data Sources At the time of writing there were no peer-reviewed published studies on aducanumab. All data presented are derived directly from the material Biogen submitted to the FDA for approval. The three studies that will be reviewed are: Multiple Dose Study of Aducanumab in Participants With Prodromal or Mild AD (PRIME), 221AD302 Phase 3 Study of Aducanumab in Early AD (EMERGE), 221AD301 Phase 3 Study of Aducanumab in Early AD (ENGAGE). Data Synthesis PRIME, which was a phase 1 study, demonstrated the most common adverse drug reactions were amyloid-related imaging abnormalities (ARIA), which occurred at rates up to 47% (10 mg/kg group), headache (25%), urinary tract infection (16%), and upper respiratory tract infection (19%). EMERGE demonstrated that high-dose aducanumab was clinically significant at slowing down clinical decline. However, ENGAGE was terminated early based on a futility analysis. Prior to termination ENGAGE demonstrated no clinical difference between treatment and placebo regarding the primary endpoint of slowing clinical decline. Conclusion Based on the data to date, it is difficult to accurately assess the role of aducanumab in patients with MCI or mild AD. EMERGE showed benefit with high-dose aducanumab slowing clinical decline. However, ENGAGE did not duplicate this benefit. With conflicting evidence of positive outcomes, future phase III studies are needed to confirm efficacy.
Similar articles
-
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.J Prev Alzheimers Dis. 2023;10(2):171-177. doi: 10.14283/jpad.2023.6. J Prev Alzheimers Dis. 2023. PMID: 36946443 Clinical Trial.
-
Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer's disease: A systematic review and network meta-analysis.Ageing Res Rev. 2022 Nov;81:101709. doi: 10.1016/j.arr.2022.101709. Epub 2022 Aug 9. Ageing Res Rev. 2022. PMID: 35961514 Review.
-
Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.Clin Interv Aging. 2022 May 18;17:797-810. doi: 10.2147/CIA.S325026. eCollection 2022. Clin Interv Aging. 2022. PMID: 35611326 Free PMC article. Review.
-
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30. J Prev Alzheimers Dis. 2022. PMID: 35542991 Clinical Trial.
-
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161. JAMA Neurol. 2022. PMID: 34807243 Free PMC article. Clinical Trial.
Cited by
-
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond.Curr Neuropharmacol. 2024;22(6):1080-1109. doi: 10.2174/1570159X22666231017141636. Curr Neuropharmacol. 2024. PMID: 37898823
-
Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.Int J Mol Sci. 2023 Sep 9;24(18):13900. doi: 10.3390/ijms241813900. Int J Mol Sci. 2023. PMID: 37762203 Free PMC article. Review.
-
Malignant Brain Aging: The Formidable Link Between Dysregulated Signaling Through Mechanistic Target of Rapamycin Pathways and Alzheimer's Disease (Type 3 Diabetes).J Alzheimers Dis. 2023;95(4):1301-1337. doi: 10.3233/JAD-230555. J Alzheimers Dis. 2023. PMID: 37718817 Free PMC article. Review.
-
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease.Mol Neurodegener. 2023 Jul 3;18(1):43. doi: 10.1186/s13024-023-00636-1. Mol Neurodegener. 2023. PMID: 37400870 Free PMC article. Review.
-
Exploring Whether Iron Sequestration within the CNS of Patients with Alzheimer's Disease Causes a Functional Iron Deficiency That Advances Neurodegeneration.Brain Sci. 2023 Mar 18;13(3):511. doi: 10.3390/brainsci13030511. Brain Sci. 2023. PMID: 36979320 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical